CA Stock MarketDetailed Quotes
FRX Fennec Pharmaceuticals Inc
- 9.275
- -0.165-1.75%
15min DelayMarket Closed Jun 14 16:00 ET
253.41MMarket Cap171.76P/E (TTM)
9.560High9.275Low1.13KVolume9.520Open9.440Pre Close10.57KTurnover15.43052wk High0.01%Turnover Ratio27.32MShares9.00052wk Low0.054EPS TTM173.43MFloat Cap130.500Historical HighLossP/E (Static)18.70MShs Float0.090Historical Low-0.795EPS LYR3.02%Amplitude--Dividend TTM61.42P/B1Lot Size--Div YieldTTM
About Fennec Pharmaceuticals Inc Company
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Company Profile
SymbolFRX
Company NameFennec Pharmaceuticals Inc
Founded1998
MarketTSE
Employees29
Fiscal Year Ends12-31
Address68 TW Alexander Drive PO Box 13628
CityResearch Triangle Park
CountryUnited States of America
Zip Code27709
Phone+1 919 636-4530
Websitehttps://www.fennecpharma.com
Company Executives
- Name
- Position
- Salary
- Rostislav Raykov
- Director and Chief Executive Officer
- 2.54M
- Robert Andrade
- Chief Financial Officer and Principal Accounting Officer
- 1.31M
- Adrian J. Haigh
- Chief Operating Officer
- 145.68K
- Dr. Khalid Islam, PhD
- Chairman of the Board
- 225.23K
- Dr. Marco M. Brughera
- Independent Director
- 166.31K
- Chris A. Rallis
- Independent Director
- 173.18K
- Dr. Jodi A. Cook, PhD
- Independent Director
- 153.81K
Heat List
CA
Overall
Symbol
Latest Price
%Chg